Spero Therapeutics (NASDAQ:SPRO) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Spero Therapeutics (NASDAQ:SPRO) from a buy rating to a hold rating in a report published on Friday, Zacks.com reports.

According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “

Several other research firms have also recently commented on SPRO. HC Wainwright reissued a buy rating and set a $27.00 target price on shares of Spero Therapeutics in a research report on Monday, August 12th. Cantor Fitzgerald reissued a buy rating and set a $27.00 target price on shares of Spero Therapeutics in a research report on Thursday, May 9th. ValuEngine upgraded shares of Spero Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. Finally, TheStreet lowered shares of Spero Therapeutics from a c- rating to a d+ rating in a research note on Monday, July 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $20.60.



Shares of NASDAQ SPRO opened at $9.78 on Friday. Spero Therapeutics has a fifty-two week low of $5.52 and a fifty-two week high of $14.48. The stock has a market cap of $182.46 million, a price-to-earnings ratio of -3.76 and a beta of 2.08. The company has a debt-to-equity ratio of 0.04, a quick ratio of 17.48 and a current ratio of 13.66. The firm’s 50-day simple moving average is $10.29 and its 200 day simple moving average is $11.52.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.10). Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%. The business had revenue of $2.16 million during the quarter, compared to the consensus estimate of $6.95 million. On average, sell-side analysts predict that Spero Therapeutics will post -2.94 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in SPRO. Marshall Wace LLP lifted its stake in shares of Spero Therapeutics by 475.8% in the second quarter. Marshall Wace LLP now owns 17,699 shares of the company’s stock worth $204,000 after buying an additional 14,625 shares in the last quarter. Novo Holdings A S bought a new position in shares of Spero Therapeutics in the second quarter worth approximately $5,363,000. Vanguard Group Inc. lifted its stake in shares of Spero Therapeutics by 4.5% in the second quarter. Vanguard Group Inc. now owns 437,204 shares of the company’s stock worth $5,032,000 after buying an additional 18,814 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Spero Therapeutics by 56.0% in the second quarter. BlackRock Inc. now owns 656,778 shares of the company’s stock worth $7,559,000 after buying an additional 235,691 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new position in shares of Spero Therapeutics in the second quarter worth approximately $115,000. Institutional investors and hedge funds own 45.08% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Further Reading: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.